← All trials
NCT05035979
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Jul 1, 2023
- Completion date
- Aug 31, 2023
- First posted
- Sep 5, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 472
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai University of Traditional Chinese MedicineLead sponsor
- Shanghai Skin Disease HospitalCollaborator
- Shanghai Yueyang Integrated Medicine HospitalStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.